CENTRAL TRUST Co Cuts Position in Cencora, Inc. (NYSE:COR)

CENTRAL TRUST Co lessened its holdings in Cencora, Inc. (NYSE:COR) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,728 shares of the company’s stock after selling 67 shares during the period. CENTRAL TRUST Co’s holdings in Cencora were worth $388,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Czech National Bank increased its stake in Cencora by 12.6% during the 3rd quarter. Czech National Bank now owns 35,536 shares of the company’s stock worth $7,998,000 after buying an additional 3,990 shares in the last quarter. GAMMA Investing LLC increased its stake in Cencora by 22.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,385 shares of the company’s stock worth $762,000 after buying an additional 623 shares in the last quarter. Azzad Asset Management Inc. ADV purchased a new stake in Cencora during the 3rd quarter worth approximately $1,824,000. Fulton Bank N.A. increased its stake in Cencora by 6.1% during the 3rd quarter. Fulton Bank N.A. now owns 5,096 shares of the company’s stock worth $1,147,000 after buying an additional 294 shares in the last quarter. Finally, Callan Family Office LLC increased its stake in Cencora by 33.7% during the 3rd quarter. Callan Family Office LLC now owns 1,718 shares of the company’s stock worth $387,000 after buying an additional 433 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 1.2 %

COR opened at $251.31 on Wednesday. Cencora, Inc. has a one year low of $214.77 and a one year high of $261.25. The stock has a market capitalization of $48.57 billion, a PE ratio of 33.46, a P/E/G ratio of 1.59 and a beta of 0.49. The business’s 50 day moving average price is $239.00 and its 200 day moving average price is $236.39. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,187 shares of company stock worth $17,790,912. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on COR. Barclays boosted their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Evercore ISI boosted their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company boosted their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. Mizuho initiated coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $278.40.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.